Abstract
Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) are among the most common malignancies of childhood. 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) can be employed for accurate staging, treatment planning, and response assessment in pediatric patients with lymphomas, taking advantage of the increased FDG uptake of the malignant cells, secondary to their increased metabolic needs. FDG PET has higher sensitivity than other imaging modalities to detect nodular or diffuse lesions and higher sensitivity than bone marrow biopsy to detect bone marrow infiltration. FDG PET consists of an invaluable imaging modality during evaluation and treatment of pediatric lymphomas.
Similar content being viewed by others
References
Abramscpcpon SJ, Price AP (2008) Imaging of pediatric lymphomas. Radiol Clin North Am 46(2):313–338. doi:10.1016/j.rcl.2008.03.009
Adams MJ, Lipsitz SR, Colan SD, Tarbell NJ, Treves ST, Diller L, Greenbaum N, Mauch P, Lipshultz SE (2004) Cardiovascular status in long-term survivors of Hodgkin’s disease treated with chest radiotherapy. J Clin Oncol 22(15):3139–3148. doi:10.1200/JCO.2004.09.10922/15/3139
Agrawal K, Mittal BR, Bansal D, Varma N, Srinivasan R, Trehan A, Manohar K, Kashyap R, Bhattacharya A, Marwaha RK (2012) Role of F-18 FDG PET/CT in assessing bone marrow involvement in pediatric Hodgkin’s lymphoma. Ann Nucl Med (EPUB). doi:10.1007/s12149-012-0665-5
Alessio AM, Kinahan PE, Manchanda V, Ghioni V, Aldape L, Parisi MT (2009) Weight-based, low-dose pediatric whole-body PET/CT protocols. J Nucl Med 50:1570–1577. doi:10.2967/jnumed.109.065912
Andolino DL, Hoene T, Xiao L, Buchsbaum J, Chang AL (2011) Dosimetric comparison of involved-field three-dimensional conformal photon radiotherapy and breast-sparing proton therapy for the treatment of Hodgkin’s lymphoma in female pediatric patients. Int J Radiat Oncol Biol Phys 81(4):e667–671. doi:10.1016/j.ijrobp.2011.01.061
Andre N, Fabre A, Colavolpe C, Jacob T, Gaudart J, Coze C, Paris M, Gentet JC, Guedj E, Michel G, Mundler O (2008) FDG PET and evaluation of posttherapeutic residual tumors in pediatric oncology: preliminary experience. J Pediatr Hematol Oncol 30(5):343–346. doi:10.1097/MPH.0b013e3181647c27
Arya LS, Dinand V, Thavaraj V, Bakhshi S, Dawar R, Rath GK, Singh R, Vats TS (2006) Hodgkin’s disease in Indian children: outcome with chemotherapy alone. Pediatr Blood Cancer 46(1):26–34. doi:10.1002/pbc.20157
Braam KI, Overbeek A, Kaspers GJ, Ronckers CM, Schouten-van Meeteren AY, Van Dulmen-Den Broeder E, Veening MA (2012) Malignant melanoma as second malignant neoplasm in long-term childhood cancer survivors: a systematic review. Pediatr Blood Cancer 58:665–674. doi:10.1002/pbc.24023
Chawla SC, Federman N, Zhang D, Nagata K, Nuthakki S, McNitt-Gray M, Boechat MI (2010) Estimated cumulative radiation dose from PET/CT in children with malignancies: a 5-year retrospective review. Pediatr Radiol 40(5):681–686. doi:10.1007/s00247-009-1434-z
Cheng G, Chen W, Chamroonrat W, Torigian DA, Zhuang H, Alavi A (2011) Biopsy versus FDG PET/CT in the initial evaluation of bone marrow involvement in pediatric lymphoma patients. Eur J Nucl Med Mol Imaging 38(8):1469–1476. doi:10.1007/s00259-011-1815-z
Cheng G, Servaes S, Zhuang H (2012) Value of (18)F-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography scan versus diagnostic contrast computed tomography in initial staging of pediatric patients with lymphoma. Leuk Lymphoma (EPUB). doi:10.3109/10428194.2012.727416
Constine LS, Tarbell N, Hudson MM, Schwartz C, Fisher SG, Muhs AG, Basu SK, Kun LE, Ng A, Mauch P, Sandhu A, Culakova E, Lyman G, Mendenhall N (2008) Subsequent malignancies in children treated for Hodgkin’s disease: associations with gender and radiation dose. Int J Radiat Oncol Biol Phys 72(1):24–33. doi:10.1016/j.ijrobp.2008.04.067
Depas G, De Barsy C, Jerusalem G, Hoyoux C, Dresse MF, Fassotte MF, Paquet N, Foidart J, Rigo P, Hustinx R (2005) 18F-FDG PET in children with lymphomas. Eur J Nucl Med Mol Imaging 32(1):31–38. doi:10.1007/s00259-004-1604-z
Dokmanovic L, Krstovski N, Vukanic D, Brasanac D, Rodic P, Cvetkovic M, Janic D (2012) Pediatric non-Hodgkin lymphoma: a retrospective 14-year experience with Berlin–Frankfurt–Munster (BFM) protocols from a tertiary care hospital in Serbia. Pediatr Hematol Oncol 29(2):109–118. doi:10.3109/08880018.2011.652342
Dores GM, Metayer C, Curtis RE, Lynch CF, Clarke EA, Glimelius B, Storm H, Pukkala E, van Leeuwen FE, Holowaty EJ, Andersson M, Wiklund T, Joensuu T, van’t Veer MB, Stovall M, Gospodarowicz M, Travis LB (2002) Second malignant neoplasms among long-term survivors of Hodgkin’s disease: a population-based evaluation over 25 years. J Clin Oncol 20(16):3484–3494
Fahey FH, Palmer MR, Strauss KJ, Zimmerman RE, Badawi RD, Treves ST (2007) Dosimetry and adequacy of CT-based attenuation correction for pediatric PET: phantom study. Radiology 243(1):96–104. doi:10.1148/radiol.243106069617
Fahey FH, Treves ST, Adelstein SJ (2012) Minimizing and communicating radiation risk in pediatric nuclear medicine. J Nucl Med Technol 40(1):13–24. doi:10.2967/jnumed.109.069609
Fakhrian K, Klemm S, Keller U, Bayer C, Riedl W, Molls M, Geinitz H (2012) Radiotherapy in stage I–III follicular non-Hodgkin lymphoma: retrospective analysis of a series of 50 patients. Strahlenther Onkol 188:464–470. doi:10.1007/s00066-011-0057-0
Freed J, Kelly KM (2010) Current approaches to the management of pediatric Hodgkin lymphoma. Paediatr Drugs 12(2):85–98. doi:10.2165/11316170-000000000-00000
Front D, Bar-Shalom R, Mor M, Haim N, Epelbaum R, Frenkel A, Gaitini D, Kolodny GM, Israel O (2000) Aggressive non-Hodgkin lymphoma: early prediction of outcome with 67 Ga scintigraphy. Radiology 214(1):253–257
Furth C, Meseck RM, Steffen IG, Schoenberger S, Denecke T, Henze G, Hautzel H, Hofheinz F, Grosser O, Hundsdoerfer P, Amthauer H, Ruf J (2012) SUV-measurements and patient-specific corrections thereof in pediatric Hodgkin lymphoma: is there a benefit for PPV in early response assessment by FDG-PET? Pediatr Blood Cancer 59:475–480. doi:10.1002/pbc.24047
Furth C, Steffen IG, Amthauer H, Ruf J, Misch D, Schonberger S, Kobe C, Denecke T, Stover B, Hautzel H, Henze G, Hundsdoerfer P (2009) Early and late therapy response assessment with [18F]fluorodeoxyglucose positron emission tomography in pediatric Hodgkin’s lymphoma: analysis of a prospective multicenter trial. J Clin Oncol 27(26):4385–4391. doi:10.1200/JCO.2008.19.7814
Hakvoort-Cammel FG, Buitendijk S, van den Heuvel-Eibrink M, Hahlen K (2004) Treatment of pediatric Hodgkin disease avoiding radiotherapy: excellent outcome with the Rotterdam-HD-84-protocol. Pediatr Blood Cancer 43(1):8–16. doi:10.1002/pbc.20031
Hermann S, Wormanns D, Pixberg M, Hunold A, Heindel W, Jurgens H, Schober O, Franzius C (2005) Staging in childhood lymphoma: differences between FDG-PET and CT. Nuklearmedizin 44(1):1–7. doi:10.1267/NUKL05010001
Hernandez-Pampaloni M, Takalkar A, Yu JQ, Zhuang H, Alavi A (2006) F-18 FDG-PET imaging and correlation with CT in staging and follow-up of pediatric lymphomas. Pediatr Radiol 36(6):524–531. doi:10.1007/s00247-006-0152-z
Hines-Thomas M, Kaste SC, Hudson MM, Howard SC, Liu WA, Wu J, Kun LE, Shulkin BL, Krasin MJ, Metzger ML (2008) Comparison of gallium and PET scans at diagnosis and follow-up of pediatric patients with Hodgkin lymphoma. Pediatr Blood Cancer 51(2):198–203. doi:10.1002/pbc.21574
Hodgson DC, Hudson MM, Constine LS (2007) Pediatric Hodgkin lymphoma: maximizing efficacy and minimizing toxicity. Semin Radiat Oncol 17(3):230–242. doi:10.1016/j.semradonc.2007.02.009
Janicek M, Kaplan W, Neuberg D, Canellos GP, Shulman LN, Shipp MA (1997) Early restaging gallium scans predict outcome in poor-prognosis patients with aggressive non-Hodgkin’s lymphoma treated with high-dose CHOP chemotherapy. J Clin Oncol 15(4):1631–1637
Kaldor JM, Day NE, Clarke EA, Van Leeuwen FE, Henry-Amar M, Fiorentino MV, Bell J, Pedersen D, Band P, Assouline D et al (1990) Leukemia following Hodgkin’s disease. N Engl J Med 322(1):7–13. doi:10.1056/NEJM199001043220102
Kasamon YL, Jacene HA, Gocke CD, Swinnen LJ, Gladstone DE, Perkins B, Link BK, Popplewell LL, Habermann TM, Herman JM, Matsui WH, Jones RJ, Ambinder RF (2012) A phase II study of rituximab-ABVD in classical Hodgkin lymphoma. Blood 119:4129–4132. doi:10.1182/blood-2012-01-402792
Kaste SC, Howard SC, McCarville EB, Krasin MJ, Kogos PG, Hudson MM (2005) 18F-FDG-avid sites mimicking active disease in pediatric Hodgkin’s. Pediatr Radiol 35(2):141–154. doi:10.1007/s00247-004-1340-3
Kostakoglu L, Agress H Jr, Goldsmith SJ (2003) Clinical role of FDG PET in evaluation of cancer patients. Radiographics 23(2):315–340, quiz 533
Levine JM, Weiner M, Kelly KM (2006) Routine use of PET scans after completion of therapy in pediatric Hodgkin disease results in a high false positive rate. J Pediatr Hematol Oncol 28(11):711–714. doi:10.1097/01.mph.0000243648.66734
Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, Rosenberg SA, Coltman CA, Tubiana M (1989) Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. J Clin Oncol 7(11):1630–1636
Lopci E, Burnelli R, Ambrosini V, Nanni C, Castellucci P, Biassoni L, Rubello D, Fanti S (2008) (18)F-FDG PET in pediatric lymphomas: a comparison with conventional imaging. Cancer Biother Radiopharm 23(6):681–690. doi:10.1089/cbr.2007.0519
Mackie EJ, Radford M, Shalet SM (1996) Gonadal function following chemotherapy for childhood Hodgkin’s disease. Med Pediatr Oncol 27(2):74–78. doi:10.1002/(SICI)1096-911X(199608)27:2<74::AID-MPO2>3.0.CO;2-Q
Magnani C, Gatta G, Corazziari I, Kramarova E, Pastore G, Viscomi S, Stiller C (2001) Childhood malignancies in the EUROCARE study: the database and the methods of survival analysis. Eur J Cancer 37(6):678–686
Miller E, Metser U, Avrahami G, Dvir R, Valdman D, Sira LB, Sayar D, Burstein Y, Toren A, Yaniv I, Even-Sapir E (2006) Role of 18F-FDG PET/CT in staging and follow-up of lymphoma in pediatric and young adult patients. J Comput Assist Tomogr 30(4):689–694
Mody RJ, Bui C, Hutchinson RJ, Frey KA, Shulkin BL (2007) Comparison of (18)F flurodeoxyglucose PET with Ga-67 scintigraphy and conventional imaging modalities in pediatric lymphoma. Leuk Lymphoma 48(4):699–707. doi:10.1080/10428190601179783
Montravers F, McNamara D, Landman-Parker J, Grahek D, Kerrou K, Younsi N, Wioland M, Leverger G, Talbot JN (2002) [(18)F]FDG in childhood lymphoma: clinical utility and impact on management. Eur J Nucl Med Mol Imaging 29(9):1155–1165. doi:10.1007/s00259-002-0861-y
Muller J, Illes A, Molnar Z, Rosta A, Varoczy L, Kovacs G (2011) Adolescent hodgkin lymphoma: are treatment results more favorable with pediatric than with adult regimens? J Pediatr Hematol Oncol 33(2):e60–63. doi:10.1097/MPH.0b013e3181f4686e
Nakatani K, Nakamoto Y, Watanabe K, Saga T, Higashi T, Togashi K (2012) Roles and limitations of FDG PET in pediatric non-Hodgkin lymphoma. Clin Nucl Med 37(7):656–662. doi:10.1097/RLU.0b013e318238f72b
Paulino AC, Margolin J, Dreyer Z, Teh BS, Chiang S (2012) Impact of PET-CT on involved field radiotherapy design for pediatric Hodgkin lymphoma. Pediatr Blood Cancer 58:860–864. doi:10.1002/pbc.23273
Purz S, Mauz-Korholz C, Korholz D, Hasenclever D, Krausse A, Sorge I, Ruschke K, Stiefel M, Amthauer H, Schober O, Kranert WT, Weber WA, Haberkorn U, Hundsdorfer P, Ehlert K, Becker M, Rossler J, Kulozik AE, Sabri O, Kluge R (2011) [18F]Fluorodeoxyglucose positron emission tomography for detection of bone marrow involvement in children and adolescents with Hodgkin’s lymphoma. J Clin Oncol 29(26):3523–3528. doi:10.1200/JCO.2010.32.4996
Sandlund JT, Downing JR, Crist WM (1996) Non-Hodgkin’s lymphoma in childhood. N Engl J Med 334(19):1238–1248. doi:10.1056/NEJM199605093341906
Schellong G, Potter R, Bramswig J, Wagner W, Prott FJ, Dorffel W, Korholz D, Mann G, Rath B, Reiter A, Weissbach G, Riepenhausen M, Thiemann M, Schwarze EW (1999) High cure rates and reduced long-term toxicity in pediatric Hodgkin’s disease: the German–Austrian multicenter trial DAL-HD-90. The German–Austrian Pediatric Hodgkin’s Disease Study Group. J Clin Oncol 17(12):3736–3744
Shankar A, Visaduraki M, Hayward J, Morland B, McCarthy K, Hewitt M (2012) Clinical outcome in children and adolescents with Hodgkin lymphoma after treatment with chemotherapy alone—the results of the United Kingdom HD3 national cohort trial. Eur J Cancer 48(1):108–113. doi:10.1016/j.ejca.2011.05.029
Sigurdson AJ, Ronckers CM, Mertens AC, Stovall M, Smith SA, Liu Y, Berkow RL, Hammond S, Neglia JP, Meadows AT, Sklar CA, Robison LL, Inskip PD (2005) Primary thyroid cancer after a first tumour in childhood (the Childhood Cancer Survivor Study): a nested case–control study. Lancet 365(9476):2014–2023. doi:10.1016/S0140-6736(05)66695-0
Sioka C, Fotopoulos A (2008) Immunotherapy and radioimmunotherapy for non-Hodgkin’s lymphoma. Cancer Therapy 6:311–320
Sklar C, Whitton J, Mertens A, Stovall M, Green D, Marina N, Greffe B, Wolden S, Robison L (2000) Abnormalities of the thyroid in survivors of Hodgkin’s disease: data from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab 85(9):3227–3232
Vose JM, Bierman PJ, Anderson JR, Harrison KA, Dalrymple GV, Byar K, Kessinger A, Armitage JO (1996) Single-photon emission computed tomography gallium imaging versus computed tomography: predictive value in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation for non-Hodgkin’s lymphoma. J Clin Oncol 14(9):2473–2479
Weiner M, Leventhal B, Cantor A, Wimmer R, Berry DL, Cook B, Ducos R (1991) Gallium-67 scans as an adjunct to computed tomography scans for the assessment of a residual mediastinal mass in pediatric patients with Hodgkin’s disease. A Pediatric Oncology Group study. Cancer 68(11):2478–2480
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sioka, C. The utility of FDG PET in diagnosis and follow-up of lymphoma in childhood. Eur J Pediatr 172, 733–738 (2013). https://doi.org/10.1007/s00431-013-1993-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00431-013-1993-8